Perioperative chemotherapy for resectable gastroesophageal cancer: A single-center experience

Molina, Raquel; Lamarca, Ángela; Martínez-Amores, B.; Gutiérrez, Alberto; Blázquez, Alma; López, Adela; Granell, Javier; Álvarez‐Mon, Melchor

doi:10.1016/j.ejso.2013.05.003

Cited by 12 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One additional RCT 6 , including mainly oesophageal and cardiac cancers along with some gastric cancers, has since been published, indicating a long‐term survival benefit from perioperative chemotherapy. Only two institutions have published their experiences with perioperative chemotherapy for gastric cancer in an everyday setting. Neither was designed to compare surgical outcomes with those of corresponding cohorts not receiving chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery

Bringeland

Wasmuth

Fougner

et al. 2014

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery

Bringeland

Wasmuth

Fougner

et al. 2014

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…We found better results in terms of both DSF and OS in patients with a good radiological response to chemotherapy assessed by CT, as we reported above (Figures 1,2) ( Table 4). The prognostic value of radiological response has been already described in previous studies (5,12,13), however its significance in patients with gastric cancer must be valued with considerable caution. Indeed, chemotherapy-induced inflammation and edema can distort the layers of the stomach wall and can lead to errors in evaluating the depth of tumor invasion (14).…”

Section: Discussionmentioning

confidence: 99%

Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study

Achilli¹,

Martini²,

Ceresoli³

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: To verify the prognostic value of the pathologic and radiological tumor response after neoadjuvant chemotherapy in the treatment of locally advanced gastric adenocarcinoma. respectively. The median follow up was 27 months (range, 5.00-68.00 months). Radiological response and TRG were found to be a prognostic factor for OS and DFS, while tumor histology was not significantly related to survival. Conclusions: Both radiological response and TRG have been shown as promising survival markers in patients treated with perioperative chemotherapy for locally advanced gastric cancer. Other predictive markers of response to chemotherapy are strongly required.

show abstract

“…Postoperative morbidity after gastric cancer resection ranges between 7.7% [35] and 57.9% [45] , and mortality between 0.0% [25,34,[46][47][48] up to 13.0% [49] . It should be noted that there is, in general, a problem in the comparability of postoperative morbidity of different studies: the criteria of postoperative morbidity either were not outlined [5,6,25,[49][50][51][52][53][54] or different criteria were included [15-20, 34, 35, 45, 46, 55-61] . For this reason, we used the Clavien-classification to compare the two groups.…”

Section: Discussionmentioning

confidence: 99%

Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer

Téoule

Trojan²,

Bechstein³

et al. 2015

Dig Surg

View full text Add to dashboard Cite

Background/Aims: Patients with locally advanced gastric cancer benefit from neoadjuvant chemotherapy. Potential disadvantages of neoadjuvant chemotherapy include increased surgical complications, leading to increased postoperative morbidity. Methods: We retrospectively studied medical records of 135 patients with resectable cancer of the stomach who underwent gastrectomy between 2002 and 2009. The impact of neoadjuvant chemotherapy on postoperative morbidity was investigated. We compared demographic, clinical and operative data, morbidity and mortality from 105 patients who received surgical treatment immediately after diagnosis (SURG group), versus 30 patients who first received neoadjuvant chemotherapy (CHEMO group). Results: Demographic, clinical and surgical procedure parameters did not differ significantly between both groups. Postoperative morbidity was 46.7% in CHEMO- and 41.9% in SURG-patients (p = 0.680). There were eight cases of death, 2/30 (6.7%) in CHEMO and 6/105 (5.7%) in the SURG group (p = 1). The overall complications according to Clavien-classification did not differ significantly (p = 0.455). The wound infection rate (23.3 vs. 3.8%; p = 0.002) and insufficiency of the duodenal stump (13.3 vs. 1.9%; p = 0.022) were significantly higher in the CHEMO group. Conclusion: This study showed no significant impact of neoadjuvant chemotherapy on postoperative morbidity after gastrectomy using the Clavien-classification. Only an increase in wound infections in CHEMO compared with the SURG group were noted. Therefore, neoadjuvant chemotherapy can be considered safe and feasible.

show abstract

Perioperative chemotherapy for resectable gastroesophageal cancer: A single-center experience

Cited by 12 publications

References 21 publications

Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery

Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery

Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study

Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer

Contact Info

Product

Resources

About